Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dipna PharmachemBOM:543594 -1.94%63 Return-on-Tangible-Asset is -0.46% as of Mar. 2026. GuruFocus rates BOM:543594 with a GF Score™ of 63/100 and a GF Value™ of ₹8.88 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 687 Healthcare Providers & Services companies, Dipna Pharmachem ranks worse than 60.7% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Dipna Pharmachem's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹-9 Mil. Dipna Pharmachem's average total tangible assets for the quarter that ended in Mar. 2026 was ₹1,916 Mil. Therefore, Dipna Pharmachem's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -0.46%.
The historical rank and industry rank for Dipna Pharmachem's Return-on-Tangible-Asset or its related term are showing as below:
BOM:543594'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.11 Med: 1.03 Max: 3.82
Current: 0.57
During the past 7 years, Dipna Pharmachem's highest Return-on-Tangible-Asset was 3.82%. The lowest was 0.11%. And the median was 1.03%.
BOM:543594's Return-on-Tangible-Asset is ranked worse than 60.7% of 687
companies
in the Healthcare Providers & Services industry
Industry Median: 2.59
vs BOM:543594: 0.57
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Dipna Pharmachem Return-on-Tangible-Asset Related Terms
Dipna Pharmachem Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Dipna Pharmachem's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -0.46% mean?
Dipna Pharmachem (BOM:543594) has a Return-on-Tangible-Asset of -0.46% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dipna Pharmachem and its competitors. Over the past decade, Dipna Pharmachem's Return-on-Tangible-Asset has ranged from 0.11 to 3.82. According to the industry distribution chart, Dipna Pharmachem ranks #417 out of 687 companies in the Healthcare Providers & Services industry, placing it in the top 60.7%.
Is Dipna Pharmachem's Return-on-Tangible-Asset too high?
Dipna Pharmachem's current Return-on-Tangible-Asset is -0.46%. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 3.82. Based on the distribution chart, Dipna Pharmachem ranks #417 out of 687 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dipna Pharmachem has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's Return-on-Tangible-Asset compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #417 out of 687 companies for Return-on-Tangible-Asset. This places Dipna Pharmachem in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.59. Historically, Dipna Pharmachem's own Return-on-Tangible-Asset has ranged from 0.11 to 3.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.59, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Dipna Pharmachem and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current Return-on-Tangible-Asset is -0.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹8.88, compared to a current price of ₹4.56 — trading 48.6% below its estimated fair value. The current Return-on-Tangible-Asset is -0.46%. Dipna Pharmachem's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current Return-on-Tangible-Asset is -0.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹4.56 is trading 48.6% below its estimated GF Value™ of ₹8.88.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
Return-on-Tangible-Asset: -0.46%
GF Value™: ₹8.88 vs. price of ₹4.56 (48.6% below fair value)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
63GF Score
Get the complete analysis for BOM:543594
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
